Issue

Vol. 26 No. 9 (2014): Vol 26 Issue 9

Copyright (c) 2014 AJC

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Evaluation of Chrysin as an Effective Antilipidemic Agent

https://doi.org/10.14233/ajchem.2014.15759
S. Vishweshwaran
School of Chemical & Biotechnology, SASTRA University, Thanjavur-613 402, India
G. Sairam
School of Chemical & Biotechnology, SASTRA University, Thanjavur-613 402, India
M. Shakilarani
School of Chemical & Biotechnology, SASTRA University, Thanjavur-613 402, India
S. Stalin
School of Chemical & Biotechnology, SASTRA University, Thanjavur-613 402, India
S. Swaminathan
School of Chemical & Biotechnology, SASTRA University, Thanjavur-613 402, India
K. Uma Maheswari
School of Chemical & Biotechnology, SASTRA University, Thanjavur-613 402, India

Corresponding Author(s) : K. Uma Maheswari

umakrishnan@sastra.edu

Asian Journal of Chemistry, Vol. 26 No. 9 (2014): Vol 26 Issue 9

Abstract

Chrysin is an flavone which is ubiquitously found in the flowers and honey of many plants. Chrysin has been found to possess anxiolytic and chemopreventive property in cardiovascular disease and cancer and it has been thus far used by male body builders. However, its role in ameliorating other diseased conditions is not yet properly investigated. The aim of the present study was to determine whether chrysin would lower the lipid levels when compared to quercetin and atorvastatin. Our results demonstrate that chrysin not only lowers total cholesterol and low density lipoprotein levels, but also triglycerides. Thus it is a potential anti-hyperlipidemic agent that could replace the currently prescribed statins that produce adverse effects on prolonged usage.

Keywords

Chrysin Atorvastatin Hyperlipidemia
Vishweshwaran, S., Sairam, G., Shakilarani, M., Stalin, S., Swaminathan, S., & Uma Maheswari, K. (2014). Evaluation of Chrysin as an Effective Antilipidemic Agent. Asian Journal of Chemistry, 26(9), 2617–2620. https://doi.org/10.14233/ajchem.2014.15759
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. U. Laufs, C. Hamm and M. Böhm, Dtsch Arztebl., 103, A-2714 (2006).
  2. R.G. Bakker-Arkema, M.H. Davidson, R.J. Goldstein, J. Davignon, J.L. Isaacsohn, S.R. Weiss, L.M. Keilson, W.V. Brown, V.T. Miller, L.J. Shurzinske and D.M. Black, JAMA, 275, 128 (1996); doi:10.1001/jama.1996.03530260042029.
  3. K.N. Gable, Hyperlipidemia Drug Class Formulary Review, Statewide Pharmacy and Therapeutics Committee (2006).
  4. M. Guerin, T.S. Lassel, W. Le Goff, M. Farnier and M.J. Chapman, Arterioscler. Thromb. Vasc. Biol., 20, 189 (2000); doi:10.1161/01.ATV.20.1.189.
  5. M.J. Chapman and A. Carrie, Arterioscler. Thromb. Vasc. Biol., 25, 2441 (2005); doi:10.1161/10.1161/01.ATV.0000194548.11901.a4.
  6. D.M. Kent, Stroke, 36, 2058 (2005); doi:10.1161/01.STR.0000185931.20915.6f.
  7. U. Ravnskov, P.J. Rosch, M.C. Sutter and M.C. Houston, BMJ, 332, 1330 (2006); doi:10.1136/bmj.332.7553.1330.
  8. B. Moosmann and C. Behl, Lancet, 363, 892 (2004); doi:10.1016/S0140-6736(04)15739-5.
  9. S.M. Grundy, Circulation, 111, 3016 (2005); doi:10.1161/CIRCULATIONAHA.105.557652.
  10. B.A. Golomb, T. Kane and J.E. Dimsdale, Q. J. Med., 97, 229 (2004); doi:10.1093/qjmed/hch035.
  11. S. Bellosta, R. Paoletti and A. Corsini, Circulation, 109, 50 (2004); doi:10.1161/01.CIR.0000131519.15067.1f.
  12. R.Y. Mukhtar and J.P. Reckless, Curr. Opin. Lipidol., 16, 640 (2005).
  13. G. Ruano, P.D. Thompson, A. Windemuth, A. Smith, M. Kocherla, T.R. Holford, R. Seip and H.B. Wu, Pharmacogenomics, 6, 865 (2005); doi:10.2217/14622416.6.8.865.
  14. H. Athar, A. R Shah and P.D. Thompson, Future Lipidol., 1, 143 (2006); doi:10.2217/17460875.1.2.143.
  15. N. Skottova, V. Krecman, P. Vana, Z. Chmela, J. Ulrichova and V. Simanek, Acta Univ. Palacki. Olomuc. Fac. Med., 144, 55 (2000); doi:10.5507/bp.2000.019.
  16. K. Hermansen, B. Dinesen, L.H. Hoie, E. Morgenstern and J. Gruenwald, Adv. Ther., 20, 50 (2003); doi:10.1007/BF02850119.
  17. Q.Y. Zhu, D.D. Schramm, H.B. Gross, R.R. Holt, S.H. Kim, T. Yamaguchi, C.L. Kwik-Uribe and C.L. Keen, Clin. Dev. Immunol., 12, 27 (2005); doi:10.1080/17402520512331329514.
  18. S. Sabatier, M.J. Amiot, M. Tacchini and S. Aubert, J. Food Sci., 57, 773 (1992); doi:10.1111/j.1365-2621.1992.tb08094.x.
  19. K.F.S. Ricardo, T.T. de Oliveira, TJ. Nagem, A. da Silva Pinto, M.G.A. Oliveira and J.F. Soares, Braz. Arch. Biol. Technol., 44, 263 (2001).
  20. A. Galijatovic, Y. Otake, U.K. Walle and T. Walle, Xenobiotica, 29, 1241 (1999); doi:10.1080/004982599237912.
  21. H.J. Jeong, Y.G. Shin, I.H. Kim and J.M. Pezzuto, Arch. Pharm. Res., 22, 309 (1999); doi:10.1007/BF02976369.
  22. I.C. Villar, R. Vera, M. Galisteo, F. O'Valle, M. Romero, A. Zarzuelo and J. Duarte, Planta Med., 71, 829 (2005); doi:10.1055/s-2005-871296.
  23. S. Miyamoto, H. Kohno, R. Suzuki, S. Sugie, A. Murakami, H. Ohigashi and T. Tanaka, Oncol. Rep., 15, 1169 (2006).
  24. A.C. Paladini, M. Marder, H. Viola, C. Wolfman, C. Wasowski and J.H. Medina, J. Pharmacol., 51, 519 (1999); doi:10.1211/0022357991772790.
  25. A. Gaw, C.J. Packard and J. Shepherd, Statins-the HMG-CoA reductase inhibitors in prespective, Martin Dunitz, London, pp. 45-58 (2004).
  26. M.H. Davidson, L. Ose, J. Frohlich, R.S. Scott, C.A. Dujovne, I.D. Escobar, M.C. Bertolami, F. Cihon, D.L. Maccubbin and M. Mercuri, Clin. Cardiol., 26, 509 (2003); doi:10.1002/clc.4960261106.
  27. A.S. Wierzbicki and D.P. Mikhailidis, Int. J. Cardiol., 84, 53 (2002); doi:10.1016/S0167-5273(02)00118-3.
  28. S. Rashid, K.D. Uffelman, H.R. Barrett and G.F. Lewis, Circulation, 106, 2955 (2002); doi:10.1161/01.CIR.0000038303.84249.4A.
  29. D.P. Mikhailidis and A.S. Wierzbicki, Libra Pharm., 16, 139 (2000).
  30. C.P. Cannon, E. Braunwald, C.H. McCabe, D.J. Rader, J.L. Rouleau, R. Belder, S.V. Joyal, K.A. Hill, M.A. Pfeffer and A.M. Skene, N. Engl. J. Med., 350, 1495 (2004); doi:10.1056/NEJMoa040583.
  31. A.S. Wierzbicki, P.J. Lumb, G. Chik and M.A. Crook, Int. J. Clin. Pract., 53, 609 (1999).
  32. J.W. Nawrocki, S.R. Weiss, M.H. Davidson, D.L. Sprecher, S.L. Schwartz, P.J. Lupien, P.H. Jones, H.E. Haber and D.M. Black, Arterioscler. Thromb. Vasc. Biol., 15, 678 (1995); doi:10.1161/01.ATV.15.5.678.
  33. B.R. Krause and R.S. Newton, Atherosclerosis, 117, 237 (1995); doi:10.1016/0021-9150(95)05576-I.
  34. L.X. Cubeddu, R.J. Cubeddu, T. Heimowitz, B. Restrepo, G.A. Lamas and G.B. Weinberg, Am. Heart J., 152, 982.e1 (2006); doi:10.1016/j.ahj.2006.08.009.
  35. R.H. Mak, Pediatr. Nephrol., 13, 891 (1999); doi:10.1007/s004670050722.
Read More
Author biographies is not available.
Download
PDF
Statistic
Read Counter : 0 Download : 1